Everything below concerns AOD9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
T-box, brain, 1 is a transcription factor protein important in vertebrate embryo development. It is encoded by the TBR1 gene. This gene is also known by several other names: T-Brain 1, TBR-1, TES-56, and MGC141978. TBR1 is a member of the TBR1 subfamily of T-box family transcription factors, which share a common DNA-binding domain. Other members of the TBR1 subfamily include EOMES and TBX21. TBR1 is involved in the differentiation and migration of neurons and is required for normal brain development. TBR1 interacts with various genes and proteins in order to regulate cortical development, specifically within layer VI of the developing six-layered human cortex. Studies show that TBR1 may play a role in major neurological diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) and autism spectrum disorder (ASD).
The few (largely space based) applications for RTGs that still exist are largely supplied by 238Pu despite its higher cost, as it has a higher power density, longer half-life and is easier shielded since it is an alpha emitter while strontium-90 is a beta emitter.
Insulin is a protein normally produced in the pancreas which regulates metabolic processes throughout the body. The primary role of insulin is to increase the metabolism of glucose, storage of energy in adipose tissue, and decrease the body's own production of glucose.
Sources: en.wikipedia.org
== Significance of work == But for Eugene Garfield's 1986 tribute to De in Current Contents, De's great contributions to cholera research would have remained unknown to many even in India. A special issue of the journal Current Science was published in 1990 in his honour, to which several eminent scientists of national and international repute contributed. In the words of Dr S Sriramachari, former director of the Institute of Pathology and additional director general of the Indian Council of Medical Research, New Delhi, De's contributions stand out as a pinnacle of excellence in our understanding of the pathogenesis of cholera. Nobel laureate Prof. Joshua Lederberg had nominated De for the Nobel Prize more than once. Said Lederberg, "our appreciation of De must then extend beyond the humanitarian consequences of his discovery. . . he is also an examplar and inspiration for a boldness of challenge to the established wisdom, a style of thought that should be more aggressively taught by example as well as precept.” De was never elected a fellow of any Indian academy and never received any major award. Indeed as Professor Padmanabhan Balaram pointed out in an editorial in Current Science, "De died in 1985 unhonoured and unsung in India's scientific circles. That De received no major award in India during his lifetime and our Academies did not see it fit to elect him to their Fellowships must rank as one of the most glaring omissions of our time.
=== Bioaccumulation and biomagnification === In marine species of the food web Bioaccumulation controls internal concentrations of pollutants, including PFAS, in individual organisms. When bioaccumulation is looked at in the perspective of the entire food web, it is called biomagnification, which is important to track because lower concentrations of pollutants in environmental matrices such as seawater or sediments, can very quickly grow to harmful concentrations in organisms at higher trophic levels, including humans. Notably, concentrations in biota can even be greater than 5000 times those present in water for PFOS and C10–C14 PFCAs. PFAS can enter an organism by ingestion of sediment, through the water, or directly via their diet. It accumulates mainly in areas with high protein content, in the blood and liver, but it is also found to a lesser extent in tissues.
== Career and research == In 1961, he took a post-doctoral fellowship at the California Institute of Technology, working with George S. Hammond, who was an organic photo-chemist. Together, they found that some catalyzed reactions can occur up to one-million times faster than non-catalyzed reactions. Intrigued by this discovery, Knowles became an enzymologist. For a brief time, Knowles was a visiting professor at Yale University. in 1974, Knowles moved his research group to Harvard and became a professor there. Knowles's research was on the boundary of chemistry and biochemistry, and concerned the rate and specificity of enzyme catalysis and the evolution of enzyme function. Early in his career, Knowles studied α-chymotrypsin and pepsin, which are nonspecific proteases, meaning they accept a broad range of substrates. He researched what made these enzymes nonspecific and how they increased the rate of peptide-bond hydrolysis. In 1972, Knowles developed a method for photo-affinity labelling, enabling the formation of a covalent bond between a protein and a ligand under the control of light. Knowles then began seminal studies on the glycolytic enzyme triosephosphate isomerase (TIM). He took advantage of its simplicity—interconverting a single substrate and a single product.
For the lighter elements, the bonds in small diatomic molecules are so strong that a condensed phase is disfavoured: thus nitrogen (N2), oxygen (O2), white phosphorus and yellow arsenic (P4 and As4), sulfur and red selenium (S8 and Se8), and the stable halogens (F2, Cl2, Br2, and I2) readily form covalent molecules with few atoms. The heavier ones tend to form long chains (e.g. red phosphorus, grey selenium, tellurium) or layered structures (e.g. carbon as graphite, black phosphorus, grey arsenic, antimony, bismuth) that only extend in one or two rather than three dimensions. Both kinds of structures can be found as allotropes of phosphorus, arsenic, and selenium, although the long-chained allotropes are more stable in all three. As these structures do not use all their orbitals for bonding, they end up with bonding, nonbonding, and antibonding bands in order of increasing energy. Similarly to group 14, the band gaps shrink for the heavier elements and free movement of electrons between the chains or layers becomes possible. Thus for example black phosphorus, black arsenic, grey selenium, tellurium, and iodine are semiconductors; grey arsenic, antimony, and bismuth are semimetals (exhibiting quasi-metallic conduction, with a very small band overlap); and polonium and probably astatine are true metals. Finally, the natural group 18 elements all stay as individual atoms.
Sources: en.wikipedia.org
=== Modern pharmacology === For most of the 19th century, drugs were not highly effective, leading Oliver Wendell Holmes Sr. to famously comment in 1842 that "if all medicines in the world were thrown into the sea, it would be all the better for mankind and all the worse for the fishes". During the First World War, Alexis Carrel and Henry Dakin developed the Carrel-Dakin method of treating wounds with an irrigation, Dakin's solution, a germicide which helped prevent gangrene. In the inter-war period, the first anti-bacterial agents such as the sulpha antibiotics were developed. The Second World War saw the introduction of widespread and effective antimicrobial therapy with the development and mass production of penicillin antibiotics, made possible by the pressures of the war and the collaboration of British scientists with the American pharmaceutical industry. Medicines commonly used by the late 1920s included aspirin, codeine, and morphine for pain; digitalis, nitroglycerin, and quinine for heart disorders, and insulin for diabetes. Other drugs included antitoxins, a few biological vaccines, and a few synthetic drugs. In the 1930s, antibiotics emerged: first sulfa drugs, then penicillin and other antibiotics. Drugs increasingly became "the center of medical practice". In the 1950s, other drugs emerged including corticosteroids for inflammation, rauvolfia alkaloids as tranquilizers and antihypertensives, antihistamines for nasal allergies, xanthines for asthma, and typical antipsychotics for psychosis. As of 2007, thousands of approved drugs have been developed.
For the above reasons, the demand for in-situ analysis is increasing. In-situ means analyzing monazite grains in their original host rocks without separation (refer to in situ) such that the texture and zonation pattern are kept intact in order to reveal a more comprehensive geological history of the host rock. Direct sampling techniques, high spatial resolution and precision are required for in-situ analysis. With technological advancement, more and more measurement tools such as laser ablation inductively coupled plasma mass spectrometry (LA-ICPMS) and laser microprobe mass spectrometer (LMMS) are capable of such analysis.
Like Truman and Eisenhower, John F. Kennedy supported containment. President Eisenhower's New Look policy had emphasized the use of less expensive nuclear weapons to deter Soviet aggression by threatening massive nuclear attacks on all of the Soviet Union. Nuclear weapons were much cheaper than maintaining a large standing army, so Eisenhower cut conventional forces to save money. Kennedy implemented a new strategy known as flexible response. This strategy relied on conventional arms to achieve limited goals. As part of this policy, Kennedy expanded the United States special operations forces, elite military units that could fight unconventionally in various conflicts. Kennedy hoped that the flexible response strategy would allow the US to counter Soviet influence without resorting to nuclear war. To support his new strategy, Kennedy ordered a massive increase in defense spending and a rapid build-up of the nuclear arsenal to restore the lost superiority over the Soviet Union. In his inaugural address, Kennedy promised "to bear any burden" in the defense of liberty, and he repeatedly asked for increases in military spending and authorization of new weapons systems. From 1961 to 1964, the number of nuclear weapons increased by 50 percent, as did the number of B-52 bombers to deliver them. The new ICBM force grew from 63 intercontinental ballistic missiles to 424. He authorized 23 new Polaris submarines, each of which carried 16 nuclear missiles. Kennedy also called on cities to construct fallout shelters.
February 18, 2009: Taiwan The Directorate General of Budget, Accounting and Statistics announced that its economy had contracted an unprecedented 8.36% in the fourth quarter of 2008; and also recorded 2 consecutive quarters of economic contraction, thus placing the country in a technical recession.
== Software and technology == Cable landing station, where a submarine cable comes ashore Common Language Specification, Microsoft CLS (command) to clear computer screen in several environments CLS (CONFIG.SYS directive), in DR-DOS Creative Lighting System, in Nikon speedlights
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.